Predictions of outcome and toxicity of stereotactic ablative radiotherapy for malignant pulmonary nodules using artificial intelligence

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200065250

Enrollment

Unknown

Registered

2022-11-01

Start date

2022-11-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Case series:None

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age 18 and older Confirmed or highly suspectful malignant pulmonary nodules Patients who are not suitable for surgeries Very old patients who reject surgeries KPS>70 Multiple malignant pulmonary nodules that are suitable for SBRT The overall survival time is longer than 3 months Patients who sign the consent form and agree for SBRT

Exclusion criteria

Exclusion criteria: Patients who are in good conditions and choose to have surgery Benign pulmonary nodules

Design outcomes

Primary

Measure	Time frame
Local control;	—

Countries

China

Contacts

Public ContactYuenan Wang

Peking University Shenzhen Hospital

yuenan_wang@163.com+86 13554725783

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026